| 000 | 01738 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513053527.0 | ||
| 264 | 0 | _c19941223 | |
| 008 | 199412s 0 0 eng d | ||
| 022 | _a0004-8291 | ||
| 024 | 7 |
_a10.1111/j.1445-5994.1994.tb01463.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRobinson, B A | |
| 245 | 0 | 0 |
_aSecond malignant neoplasms in patients with Hodgkin's disease. _h[electronic resource] |
| 260 |
_bAustralian and New Zealand journal of medicine _cAug 1994 |
||
| 300 |
_a368-73 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aChlorambucil _xadministration & dosage |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHodgkin Disease _xtherapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMechlorethamine _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms, Second Primary _xepidemiology |
| 650 | 0 | 4 |
_aNew Zealand _xepidemiology |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 |
_aProcarbazine _xadministration & dosage |
| 650 | 0 | 4 | _aRadiotherapy Dosage |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aVinblastine _xadministration & dosage |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 700 | 1 | _aColls, B M | |
| 700 | 1 | _aFitzharris, B M | |
| 700 | 1 | _aAtkinson, C H | |
| 773 | 0 |
_tAustralian and New Zealand journal of medicine _gvol. 24 _gno. 4 _gp. 368-73 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1445-5994.1994.tb01463.x _zAvailable from publisher's website |
| 999 |
_c7979562 _d7979562 |
||